儿童肿瘤学组 2023 年研究蓝图：药学。
Children's Oncology Group's 2023 blueprint for research: Pharmacy.
机构信息
Department of Pharmacy, University of Mississippi Medical Center, Children's of Mississippi, Jackson, Mississippi, USA.
Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
出版信息
Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30581. doi: 10.1002/pbc.30581. Epub 2023 Jul 17.
Abstract
Children's Oncology Group (COG) pharmacists and pharmacy technicians from more than 200 COG-member institutions comprise the COG Pharmacy Discipline. Discipline members serve an essential role in the design and execution of COG clinical trials. Core activities include study drug management, study drug access, clinical trial operations, protocol harmonization, and direct patient care. Discipline members are also actively involved in continuing education, membership engagement, and research across other COG committees/domains. Future areas of committed growth for the discipline include pharmacogenomics, pharmacokinetics, pharmacoeconomics, pharmaceutics, and implementation science.
摘要
儿童肿瘤学组（COG）的药剂师和药剂技术员来自 200 多个 COG 成员机构，组成了 COG 药房学科。学科成员在 COG 临床试验的设计和实施中发挥着重要作用。核心活动包括研究药物管理、研究药物获取、临床试验操作、方案协调以及直接患者护理。学科成员还积极参与其他 COG 委员会/领域的继续教育、会员参与和研究。该学科未来的重点发展领域包括药物基因组学、药代动力学、药物经济学、药剂学和实施科学。
相似文献
1
Children's Oncology Group's 2023 blueprint for research: Pharmacy.儿童肿瘤学组 2023 年研究蓝图：药学。
Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30581. doi: 10.1002/pbc.30581. Epub 2023 Jul 17.
2
Children's Oncology Group 2023 blueprint: Nursing discipline.儿童肿瘤学组 2023 年蓝图：护理学科。
Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30575. doi: 10.1002/pbc.30575. Epub 2023 Jul 20.
3
Children's Oncology Group's 2023 blueprint for research: Young investigators.儿童肿瘤学组 2023 年研究蓝图：青年研究人员。
Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30567. doi: 10.1002/pbc.30567. Epub 2023 Jul 12.
4
Survey to assess the role of pharmacy technicians and nonpharmacist staff in the operation of research pharmacies.评估药房技术员和非药剂师工作人员在研究药房运营中作用的调查。
Am J Health Syst Pharm. 2014 Nov 1;71(21):1877-89. doi: 10.2146/ajhp140007.
5
Children's Oncology Group's 2023 blueprint for research: Diversity and health disparities.儿童肿瘤学组 2023 年研究蓝图：多样性和健康差异。
Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30592. doi: 10.1002/pbc.30592. Epub 2023 Jul 28.
6
Educational needs of oncology pharmacists: A survey by the International Society of Oncology Pharmacy Practitioners.肿瘤药学教育需求：国际肿瘤药学实践协会调查。
J Oncol Pharm Pract. 2021 Apr;27(3):623-634. doi: 10.1177/1078155220929754. Epub 2020 Jun 15.
7
Children's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology.儿童肿瘤学组 2013 年研究蓝图：青少年及青年肿瘤学。
Pediatr Blood Cancer. 2013 Jun;60(6):1055-8. doi: 10.1002/pbc.24431. Epub 2012 Dec 19.
8
Evaluation of the effects of a drug with fiscalized substance dispensation, health education, and pharmacovigilance continuing education program in Colombia drugstores and drugstores/pharmacies: study protocol of a multicenter, cluster-randomized controlled trial.评价具有财政化物质配给、健康教育和药物警戒继续教育项目的药物对哥伦比亚药店和药店/药房的影响：一项多中心、集群随机对照试验的研究方案。
Trials. 2020 Jun 19;21(1):545. doi: 10.1186/s13063-020-04481-1.
9
The impact of chemotherapy shortages on COG and local clinical trials: a report from the Children's Oncology Group.化疗药物短缺对儿童肿瘤协作组及当地临床试验的影响：来自儿童肿瘤学组的报告
Pediatr Blood Cancer. 2015 Jun;62(6):940-4. doi: 10.1002/pbc.25445. Epub 2015 Feb 19.
10
Health-system specialty pharmacy: Overview of a hybrid clinical model.医疗体系专科药房：混合临床模式概述。
Am J Health Syst Pharm. 2024 Apr 19;81(9):e256-e260. doi: 10.1093/ajhp/zxad333.
本文引用的文献
1
Essential medicines for childhood cancer in Europe.欧洲儿童癌症基本药物。
Lancet Oncol. 2023 Feb;24(2):e67. doi: 10.1016/S1470-2045(23)00009-8.
2
Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype.扩展临床药物遗传学实施联盟指南：G6PD 基因型背景下的药物使用
Clin Pharmacol Ther. 2023 May;113(5):973-985. doi: 10.1002/cpt.2735. Epub 2022 Sep 24.
3
The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children's Oncology Group and NRG Oncology study ARST1321.帕唑帕尼对儿童和成人非横纹肌肉瘤软组织肉瘤患者多柔比星药代动力学的影响：来自儿童肿瘤学组和 NRG 肿瘤学研究 ARST1321 的报告。
Cancer Chemother Pharmacol. 2022 Apr;89(4):551-557. doi: 10.1007/s00280-022-04397-4. Epub 2022 Jan 27.
4
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.Inotuzumab Ozogamicin 治疗儿童和青少年复发/难治性 B 细胞急性淋巴细胞白血病的 II 期临床试验：儿童肿瘤学组协议 AALL1621。
J Clin Oncol. 2022 Mar 20;40(9):956-967. doi: 10.1200/JCO.21.01693. Epub 2022 Jan 10.
5
Incorporating G6PD genotyping to identify patients with G6PD deficiency.将 G6PD 基因分型纳入以鉴定 G6PD 缺乏症患者。
Pharmacogenet Genomics. 2022 Apr 1;32(3):87-93. doi: 10.1097/FPC.0000000000000456.
6
Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group.升高的药物费用对中危横纹肌肉瘤两种化疗方案成本效益的影响：来自儿童肿瘤协作组的报告。
Cancer. 2022 Jan 15;128(2):317-325. doi: 10.1002/cncr.33917. Epub 2021 Oct 8.
7
Facilitators and barriers to clinical practice guideline-consistent supportive care at pediatric oncology institutions: a Children's Oncology Group study.儿科肿瘤机构中临床实践指南一致的支持性护理的促进因素和障碍：一项儿童肿瘤学组研究
Implement Sci Commun. 2021 Sep 16;2(1):106. doi: 10.1186/s43058-021-00200-2.
8
Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event-free survival in intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group.环磷酰胺药代动力学候选基因与中危横纹肌肉瘤无事件生存的药物基因组学关联：来自儿童肿瘤组的报告。
Pediatr Blood Cancer. 2021 Nov;68(11):e29203. doi: 10.1002/pbc.29203. Epub 2021 Jul 10.
9
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.新诊断高危神经母细胞瘤患者诱导化疗后白消安/美法仑清髓巩固治疗：儿童肿瘤协作组试验ANBL12P1
Transplant Cell Ther. 2021 Jun;27(6):490.e1-490.e8. doi: 10.1016/j.jtct.2021.03.006. Epub 2021 Mar 6.
10
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.Blinatumomab 巩固化疗后与化疗对初发 B 细胞急性淋巴细胞白血病儿童、青少年和年轻成人患者无病生存的影响：一项随机临床试验。
JAMA. 2021 Mar 2;325(9):833-842. doi: 10.1001/jama.2021.0669.
Zotero 插件